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with patients randomized to placebo (3.8 years (95% CI: 3.3–4.2) for
BQ-123 versus 2.8 years (2.1-3.4) for placebo, p = 0.032, Figure 1).
Conclusion: Short-term administration of BQ-123 in patients undergo-
ing primary PCI for STE-ACS leads to a longer cardiovascular event-free
survival.
doi:10.1016/j.lfs.2014.01.034
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Introduction: Little has been known about clinical background of
the patients with heart failure (HF) and sleep disordered breathing
(SDB). The aim of this study was to elucidate the relationship
between HF and SDB. Methods: 1121 patients admitted to our
institute with the diagnosis of HF between 2006 and 2012 was
enrolled. SDB was deﬁned N5/h of apnea–hypopnea index (AHI).
Obstructive sleep apnea (OSA) group and central sleep apnea (CSA)
group were deﬁned based on the data of type III sleep monitor
(Morpheus). Results: Among 1121 patients 328 (29%) underwent
screening of type III sleep monitor. In the 328 patients, 275 (84%)
patients showed SDB. Among these 275 SDB patients, 135 (41%)
were OSA, and 140 (43%) were CSA. AHI was signiﬁcantly higher
(OSA: 22.5 ± 16.2, CSA: 29.8 ± 14.9, P b 0.05) and ejection fraction
(EF) was signiﬁcantly lower (OSA: 40.1 ± 17.1%, CSA: 33.5 ± 14.1%,
P b 0.05) in CSA group between two groups. Among 140 CSA
patients, 80 (57%) patients have heart failure with reduced ejection
fraction (HFREF) and among 135 OSA patients, 60 (44%) patients
have HFREF. Conclusions: SDB was highly associated with HF and the
clinical features between OSA and CSA with HF were different. CSA
patients were associated with lower EF and higher AHI than OSA
patients. This study suggested that SDB was one of an important
target of treatment HF and to treat HF according to these clinical
subsets of SDB was clinically required in the future.
doi:10.1016/j.lfs.2014.01.035
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Pharmacological inhibition and genetic deletion (Murakoshi et al.,
2002; Kirkby et al., 2012) suggest that endothelin (ET) A-selective
antagonists are preferable to mixed ETA/B antagonists for prevention of
neointimal lesion formation. ETB receptors expressed in smoothmuscle
cells may, however, contribute to lesion development. It was proposed
that ETB deletion from smooth muscle (SM) would reduce lesion
formation following arterial injury. Methods: Mice bearing a ﬂoxed ETB
gene or expressing cre-recombinase under the SM22 promoter were
crossed to produce SM-selective ETB deletion. SMETB knockout mice
were identiﬁed by genotyping and backcrossed to C57Bl/6J (4–6
generations). Functional conﬁrmation of ET deletion was determined
by exposing trachea, and mesenteric artery and vein, to sarafotoxin 6c
in a myograph. Femoral injury was performed in adult, male SMETB
knockout mice and littermate controls and arteries were harvested
33 days later for structural analysis. Results: SMETB knockout reduced
(~55%), but did not abolish, ETB-mediated contraction in trachea. In
contrast, S6c-mediated contraction in mesenteric veins (130+ 46%
KPSS, n = 4), and in mesenteric arteries cultured for 24 h (72 + 24%
KPSS, n = 4), was abolished by SMETB deletion (5.1 + 3.4% KPSS and
0% KPSS, respectively). Femoral artery injury produced large, neointi-
mal lesions (47.4 + 10.6%; n = 7) but SMETB knockout did not alter
lesion size (42.2 + 4.5%; n = 9; P = 0.64). Conclusions: Stimulation of
ETB receptors in SM does not inﬂuence neointimal lesion formation.
This supports the suggestion that ETA-selective antagonists are
preferable to non-selective antagonists for prevention of neointimal
proliferation. The study was funded by the BHF (project grant and
CoRE). Murakoshi et al. (2002) Circulation 106:15; Kirkby et al. (2012)
Cardiovasc Res, 95, 19.
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Incubation of arteries ex vivo induces ETB-mediated contraction
(Adner et al., 1998), possibly via transcriptional mechanisms (Skovsted
et al., 2012). ETB receptors are also expressed in neointimal lesions
(Azuma et al., 1994). It was proposed that ETB-mediated contraction
would be induced by neointimal lesion formation. Methods: Femoral
arteries from adult, male C57Bl/6J mice (n= 6) were harvested 36 +/
− 2 days after ligation. Isolated mesenteric and femoral veins and
arteries from uninjured mice were cultured (DMEM; 37 °C; 5% CO2;
5 days) before analysis in a myograph. Contractile function was as-
sessed using phenylephrine (10−9–3 × 10-5 M), endothelin-1 (10−11–
10−7M) and sarafotoxin 6c (10−11–10−7M). Relaxant function
was assessed using endothelium-dependent (acetylcholine; 10−9–3 ×
10−5 M) and independent (sodium nitroprusside; 10−9–3 × 10−5M)
agents after contraction with phenylephrine. Results: Freshly isolated
mesenteric veins contracted in response to S6c whereas mesenteric
arteries and femoral veins did not. Some (4/10) femoral arteries
produced small S6c-induced contractions (21.86 +/− 3.72% KPSS,
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